Jiangsu Yahong Meditech Co., Ltd. (JIANGSU YAHONG MEDITECH CO LTD) aksje

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic therapy product for the treatment of high-grade squamous intraepithelial lesions of the cervix, as well as for HPV virus clearance indication; APL-1706 and APLD-2304 for non-muscle invasive bladder cancer (NMIBC) diagnosis and surgery indication; APL-1202, an oral reversible MetAP2 inhibitor for untreated intermediate-risk NMIBC and neoadjuvant therapy before muscle-invasive bladder cancer indication, as well as for free-living amoeba infection indication; APL-1501 and APL-2401 to treat urinary system tumors. The company also develops product candidates for the treatment of breast cancer and gynecological tumors under the APL-2302, APL-2501, AT-018, and AT-021 names. In addition, it develops APL-1401, a dopamine ß- hydroxylase inhibitor to treat moderate to severe active ulcerative colitis; and APL-2301 for treating infections caused by acinetobacter baumannii. The company was founded in 2010 and is based in Shanghai, China.